Fulcrum Therapeutics (FULC) Cash & Equivalents (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Cash & Equivalents data on file, last reported at $333.3 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $333.3 million, up 690.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $333.3 million (up 690.26% YoY), and the FY2025 annual result was $197.5 million, down 18.04% from the prior year.
• Cash & Equivalents improved to $333.3 million in Q1 2026 per FULC's latest filing, from $197.5 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $333.3 million in Q1 2026 and troughed at $30.1 million in Q3 2023.
• A 5-year average of $106.4 million and a median of $47.1 million in 2025 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2026: Cash & Equivalents sank 66.93% in 2022, then jumped 690.26% in 2026.
• A 5-year view of Cash & Equivalents shows it stood at $35.1 million in 2022, then soared by 573.03% to $236.2 million in 2023, then gained by 2.03% to $241.0 million in 2024, then dropped by 18.04% to $197.5 million in 2025, then soared by 68.74% to $333.3 million in 2026.
• Business Quant data shows FULC's Cash & Equivalents at $333.3 million in Q1 2026, $197.5 million in Q4 2025, and $47.1 million in Q3 2025.